key: cord-1006428-xuc2sobe
authors: Regazzoni, Francesco; Vergara, Christian; Dede’, Luca; Zunino, Paolo; Guglielmo, Marco; Scrofani, Roberto; Fusini, Laura; Cogliati, Chiara; Pontone, Gianluca; Quarteroni, Alfio
title: Modeling the effect of COVID-19 disease on the cardiac function: a computational study
date: 2020-06-25
journal: bioRxiv
DOI: 10.1101/2020.06.23.166421
sha: 7510ea4cef5d998e17a23088686ed131162cb332
doc_id: 1006428
cord_uid: xuc2sobe

Background The effect of COVID-19 on the cardiac function and on the vascular system increases the morbidity and mortality of infected subjects with cardiovascular diseases. Objectives To provide preliminary results on cardiac global outcomes (such as cardiac output, ventricular pressures) obtained by means of computational models in plausible scenarios characterized by COVID-19. Methods We considered a lumped parameters computational model of the cardiovascular system, which models, from the mechanical point of view, the systemic and pulmonary circulations, the four cardiac valves and the four heart chambers, through mathematical equations of the underlying physical processes. To study the effect of COVID-19, we varied the heart rate, the contractility and the pulmonary resistances in suitable ranges. Results Our computations on individuals with both otherwise normal and impaired cardiac functions revealed that COVID-19 worsen cardiac function, as shown by a decrease of some cardiac biomarkers values such as cardiac output and ejection fraction. In the case of existing impaired cardiac function, the presence of COVID-19 lead to values outside the normal ranges. Conclusions Computational models revealed to be an effective tool to study the effect of COVID-19 on the cardiovascular system. Such effect could be significant for patients with impaired cardiac function. This is especially useful to perform a sensitivity analysis of the hemodynamics for different conditions. CONDENSED ABSTRACT Emerging studies address how COVID-19 infection might impact the cardiovascular system. This relates particularly to the development of myocardial injury, acute coronary syndrome, myocarditis, arrhythmia, and heart failure. Prospective treatment approach is advised for these patients. By the assessment of conventional important biomarkers obtained with new sources as a 0-dimentional computational model, we propose a new study protocol as an effective method to evaluate short-term prognosis. The clinical protocol proposed will help to rapidly identify which patients require intensive monitoring, diagnostic strategy and most adequate therapy.

caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily affects the respiratory system, although others organ systems are also involved and in particular cardiovascular complications may occur. Among patients with COVID-19, there is a high prevalence of previous history of cardiovascular diseases (CVD) and/or CVD risk factors and increased morbidity and mortality in those patients have been recently reported in several studies . The virus invades cardiomyocytes by binding to angiotensin converting enzyme 2 on the cell surface, resulting in myocardial injury which elevates troponin I levels. In particular, the COVID-19 infection can lead to myocarditis, vascular inflammation, arrhythmias, acute heart failure, and in the most severe cases, cardiogenic shock and death . Studies of patients with COVID-19 in China indicated significantly higher in-hospital mortality rate in patients who also have myocardial injury. Acute infections increase the risk of acute coronary syndrome. COVID-19 may increase circulating cytokines, which have the potential to cause instability and rupture of atherosclerotic plaques. Fever, stress, electrolyte disturbances and use of antiviral drugs in patients with COVID-19 may all have pro-arrhythmic effects. This may be an issue for patients with inherited arrhythmia syndromes, such as long QT syndrome, Brugada syndrome, short QT syndrome and catecholaminergic polymorphic ventricular tachycardia. For these patients, additional precautions and specialised management are advised. Moreover, some studies highlighted that, for patients hospitalized with COVID-19, a higher rate of comorbidities including hypertension and coronary artery disease characterized fatal events when compared to survivors [Z-Lancet-20] and myocardial injury was prevalent . In any case, the interplay of COVID-19 with cardiovascular complications both in healthy individuals and in patients with pre-existing CVD is still far from being fully understood. The mechanisms of cardiac injury in patients with COVID-19 are not well established but it is reasonable to identify both direct and indirect mechanisms responsible for cardiac failure. Possible causes of the effect of COVID-19 on cardiac impairment are due to an increased pulmonary vascular resistance consistent with severe hyperinflammation and micro-thrombosis ]. On the other side, the decreased blood saturation secondary to respiratory failure may hamper the cardiomyocytes contractility, possibly leading to a decreased cardiac output. Both as compensatory mechanism for the reduced oxygen concentration in blood and consequence of fever rise due to the COVID-19 inflammation, the heart rate may significantly increase. In this study, we provided examples of possible scenarios that investigate the effect of COVID-19 on some cardiac features of interest and other vital parameters. With this aim, we exploited the predictive nature of computational methods that are based on the numerical solution (i.e. aided by a computer) of the mathematical equations underlying the physical processes under investigation. In this context, a zero-dimensional (0D, also known as lumped parameters) model that simulates systemic and pulmonary blood dynamics together with the cardiac function has been considered [O-ABE-00]. This tool can account for a broad range of the model parameters, to simulate variations in pulmonary resistances, heart rate, and cardiomyocyte contractility in accordance with COVID-19 infection, and to compute the corresponding changes of some meaningful outputs such as stroke volume, ejection fraction, cardiac output, arterial and pulmonary pressures. The use of a 0D mathematical model allowed us to better understand the strong interplay between local changes (such as the reduced contractility), global variables (such as peripheral resistances, heart rate) and cardiac function. This is of utmost importance in view of determining the possible effects of COVID-19 infection on patients affected by CVD and, on the other hand, to better evaluate the impact of CVD on COVID-19. A possible scenario of COVID-19 infection in an individual exhibiting a reduced ejection fraction and cardiac output is investigated to sustain the power of our computational study and its possible use for patient-specific studies.

A 0D model provides a mathematical description of the function of several compartments in the cardiovascular system; their number and locations depend on the complexity of the model at hand and its level of detail. The model consists in a system of differential equations that translate physical principles such as conservation of mass and momentum. Its solution provides the values of flow rates and pressures for each compartment [R-CVS-01]. This system can be obtained by exploiting the electric analogy, where the current represents the blood flow, the voltage is the pressure, the resistance represents the blood resistance, the conductance the vessel compliance, and the inductance the blood inertia.

Referring to Figure 1 , our 0D model was composed by:

-The four heart chambers, whose mechanical behavior was characterized by suitable model parameters. For example, for the left ventricle (LV) the unloaded volumes (i.e. volume at zero-pressure) V0LV and the time-varying elastances ELV(t)=EBLV + EALV * fLV (t) were considered, where EBLV is the passive elastance (i.e the inverse of the compliance), EALV the maximum active elastance, and fLV a function of time ranging values between 0 and 1 that accounts for the activation phases. Similar parameters definitions were introduced for the right ventricle (RV), left atrium (LA), and right atrium (RA); -The four cardiac valves modeled as diodes; -The systemic circulation, characterized by the arterial resistance, compliance and inductance RAR SYS , CAR SYS , LAR SYS , respectively, and by the same quantities related to the venous system, i.e. RVEN SYS , CVEN SYS , LVEN SYS ; -The pulmonary circulation, characterized as above by the systemic parameters RAR PUL , CAR PUL , LAR PUL , and by the venous ones RVEN PUL , CVEN PUL , LVEN PUL .

For a recent study on a 0D model accounting for the pulmonary circulation, see also .

The quantities mentioned in the previous list are the parameters of the model and, together with the heart rate (HR), they fully characterize the individual or patient's condition (healthy or non-healthy). The 0D model thus provides a tool that is able to compute flow rate and pressure at each compartment given a chosen set of parameters. With this aim, we identified three sources of changes in the abovementioned parameters and corresponding reasonable value ranges:

-HR: Clinical evidences showed that tachycardia was very common in COVID-19 patients [X-EHJ-20]. Accordingly, we placed the values of HR in the range [60,100] bpm; -Wood number (W): It is defined as W= (RAR PUL + RVEN PUL ) * 1000 / 60 and represents an information about the pulmonary resistances. Since, according to clinical evidences [Q-CC-20], pulmonary resistances (and thus W) increase in presence of COVID-19, we placed the value of W in the range between 1.13 (healthy) and 3.39. More precisely, we multiplied the baseline value RVEN PUL -BASE (see Table 1 ) by a factor kR in the range [1,3]: RVEN PUL = kR* RVEN PUL -BASE (1) We also assumed that RAR PUL /RVEN PUL = 9/10 [H-IJNMBE-17]. Analogous definitions hold true for the systemic resistances; EAXX: Clinical evidences showed that COVID-19 may produce a decreased blood saturation and consequently also a decreased cardiomyocyte contractility. To account for this, we decreased the value of the four active elastance EAXX by multiplying the baseline values EAXX-BASE (see Table 1 

First, we considered the setting reported in Table 1 , corresponding to a patient in healthy conditions, henceforth denoted as baseline (bsln). In Figure 2 we reported the outcomes predicted by the 0D model for this baseline setting. Our computational model allowed to reproduce the ventricle pressurevolume (PV) loops as well as the evolution in time of volumes and pressures. Table 2 With the baseline setting as a starting point, we investigated the effect of the variations mentioned in the Methods section, to study a possible impact of COVID-19 on the cardiac function. In particular, we considered two settings, corresponding to a mild and to a more severe COVID-19 infection, that we denoted as Test (1a) and Test (1b), respectively. In Test (1a), to reflect the effects of a reduced blood saturation due to the impaired pulmonary function, we decreased the contractility of the whole heart muscle to the 85% of the baseline value. Moreover, we increased HR from 72 bpm to 86 bpm and we increased the pulmonary resistance by a factor 2 (this corresponds to a Wood number 2.26). In Test (1b), instead, we accentuated the three abovementioned effects, with a contractility of 70% of the baseline, a HR of 100 bpm and an increase of the pulmonary resistances of a factor 3 (Wood number 3.39). The PV loops corresponding to the settings (1a) and (1b) are shown in Figure 3A , while Table 2 reports the corresponding cardiac measurements. These tests showed that the LV PV loops was impacted by the hypoxemia that reduced their contractility. Overall, compared to baseline values, the reduced cardiac contractility provides a decrease in SV of 21% for Test (1a) and 38% for Test (1b), together with a reduction in LV EF of 11% and 25% for Test (1a) and Test (1b), respectively. This effect was partially compensated by the increase of HR, which can be considered in hypoxic patientsas a self-regulatory mechanism aimed to preserve the CO [B-PLOS-18]. As a matter of fact, the CO decreased of 6% from baseline for Test (1a) and of 13% for Test (1b). Besides the LV function, also the RV function is significantly affected by COVID-19 related variations of the circulation model. Specifically, RV EF decreased of 20% (Test (1a)) and 39% (Test (1b)), thus in percentage more than for LV. Moreover, the increased pulmonary resistance induced a remarkable growth of the RV maximal pressure (20% and 40% for Test (1a) and (1b), respectively) and the RV ESV reports a significant increase (34% and 78%).

We further exploited the predictive power of our computational model by simulating the effects of COVID-19 infection for an individual with mildly impaired LV cardiac function. In particular, we assumed that for this subject, in absence of COVID-19, contractility was decreased to 70% of baseline, HR equal to 60 bpm, pulmonary resistance equal to 1.70 Wood (x1.5 of baseline) and systemic resistance equal to 26.25 (x1.75 of baseline) (Test (2), see Table 3 ). The outputs computed by the 0D model were: CO = 4.1 L/min, LV SV = 68 mL, LV EF = 50% and RV EF = 53% ; furtherly, we found LV EDV = 135 mL, LV ESV = 67 mL, RV EDV = 127 mL, RV ESV = 59 mL, that however were still in the normal ranges [M-EHJ-06, M-JCMR-06, C-BMC-09].

As in Test (1), we considered two scenarios of COVID-19 infections by furtherly decreasing the heart contractility (to 60% and 50% of baseline), increasing the HR (to 72 and 85 bpm) and increasing the pulmonary resistance (to 2.54 and 3.39 Wood) for Tests (2a) and (2b), respectively. The data and results are reported in Figure 3B and Table 3 . The outputs of our numerical simulations highlighted that, in an individual with impaired LV cardiac function, the COVID-19 infection furtherly worsen the cardiac functional parameters of both chambers. In particular, we found a reduction in LV EF of 14% and 30% for Test (2a) and Test (2b), respectively, in LV EF of 14% and 30%, in RV EF of 19% and 38%, and in CO of 5% and 10%.

Our computational model is able to predict possible effects of COVID-19 infection on the cardiocirculatory system, and particularly on the cardiac function. Our study confirmed that the infection is able to impact both the left and right hearts, by decreasing EF and CO, whose decrements are only partially compensated by the HR increase that typically is shown in COVID-19 patients. Maximum LV pressure was reduced, while maximum RV pressure was increased, albeit the latter remains within the normal range of values. Our computational model predicted that the right heart is strongly linked, from the physiopathological standpoint, to the pulmonary function. Indeed, the increased pulmonary resistance significantly affects both the RV pressure and the RV EF.

These results seem to be well in keeping with recent data reporting that lower RV systolic function echocardiographic parameters, although still in the normal range, are more frequent in Covid patients with poor prognosis, thus suggesting that the absence of an increase in contractility in response to an increase in pulmonary resistance/pressures could play a role in the evolution of the illness [L-JACC-20].

As the respiratory failure worsen, RV function is supposed to be more susceptible to impairment due to increased RV afterload and in fact we have reported a progressive decrease in RV EF volume from Test (1a) to Test (1b) for a previously healthy subject. Since recent reports [M-JAMA-20, G-JAMA-20, R-ICM-20, Z-Lancet-20, L-JACC-20] suggest that CVD is a common finding in patients with COVID-19 and is associated with a worse prognosis, we also simulated the cardiac function and its response to COVID-19 in a patient with history of cardiac dysfunction. Although we measured a reduction in LV EF when we simulate a worse COVID-19 infection, we measured a more severe reduction in RV EF compared to the reduction in LV EF and this finding could explain the worse outcome in case of previous CVD. In fact, RV dysfunction is known to be an important determinant of symptoms and a powerful marker of poor prognosis in patients with chronic heart failure [G-EJHF-17, C-CCI-18].

To predict the effect of the reduced contractility, we estimated the End Systolic Pressure Volume Relationship (ESPVR) as the slope of the PV loop curve in the upper left corner. As a matter of fact, as highlighted by Figures 3A and 3B , left, the depressed inotropy reflected in a decreased ESPVR. This effect has been reported in several experiments as a direct consequence of the reduced oxygen blood content [W-CR-88, B-PLOS-18]. Moreover, the LV function experienced a reduced systolic pressure and a reduced preload, thus resulting in a significant decrease of the PVA (pressure-volume area), a further biomarker that is known to correlate with hypoxia [K-AJP-65, B-PLOS-18].

From our preliminary study, we highlighted that COVID-19 infection in a patient with healthy cardiac function may be able to produce alterations that maintain biomarkers within the normal range of values. Conversely, starting from a scenario of an individual with impaired cardiac function, where however the values of biomarkers were within normal ranges [M-EHJ-06, M-JCMR-06, C-BMC-09], our simulations revealed that the COVID-19 infection could further worsen the cardiac biomarkers, specifically by further reducing CO and SV below the normal values, other than severely impacting the LV and RV EFs.

The computational model has been proposed to carry out sensitivity analyses in a very rapid, reliable and reproducible way. It compares the effect of very complex clinical situation of the patient employed in the medical practice on the outcome of treatments in several relevant cases.

This study was based on a 0D computational model, which considers compartmental flow rates and pressures. A more detailed study for predicting pointwise quantities of interest in the heart could be carried out by means of a 3D-0D model, where the heart (or a part of it) is simulated by means of a 3D electromechanical model, whose geometry can be personalized starting from clinical images (CT or MRI) acquired from a specific patient. This is currently under study (Regazzoni F, Salvador M, Africa P, Fedele M, Dede' L, Quarteroni A. Electromechanical modeling of the human heart coupled with a circulation model of the whole cardiovascular system, in preparation).

Our computational model neglected the effect of pressure variations due to respiration on the rib cage, hence on the cardiocirculatory system. Albeit we deem this assumption to have a very limited impact on the outcomes of this study, we plan to improve our 0D model for further studies on this topic.

Computational models could be an effective tool to study the effect of COVID-19 on the cardiac function. Our preliminary 0D model computations revealed a possible worsening of SV, CO, LV EF and RV EF and other biomarkers both for individuals with otherwise normal cardiac function and with impaired cardiac function. In the latter case, these values were below normal values even if they were within normal ranges in the case without COVID-19 effects. This provided a quantitative, although speculative, confirmation that COVID-19 could have important consequences on the cardiac function. Table 1 Baseline values of the parameters used in the 0D model. Table 3 . Model parameters for simulating the effects of mild (Test (2b)) and severe (Test (2c)) COVID-19 infections in an individual with impaired cardiac function (Test (2a)), and computed outputs. For the pulmonary resistances and maximum active elastances current values are derived by the baseline ones owing to equations (1) and (2). Baseline: kR =1, kEA =100. Pictures of computed output in Figure 3B 

Potential Effects of Coronaviruses on the Cardiovascular System -A Review

Cardiovascular Implications of Fatal Outcomesof Patients With Coronavirus Disease 2019 (COVID-19)

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection

Potential for Lung Recruitment and Ventilation-Perfusion Mismatch in Patients With Acute Respiratory Distress Syndrome From Coronavirus Disease 2019

Mathematical Modelling of the Human Cardiovascular System -Data, Numerical Approximation, Clinical Applications

Numerical simulation and experimental validation of blood flow in arteries with structured-tree outflow conditions

Coupling between lumped and distributed models for blood flow problems

Integrated cardiorespiratory system model with short timescale control mechanisms

A monolithic 3D-0D coupled closed-loop model of the heart and the vascular system: Experiment-based parameter estimation for patient-specific cardiac mechanics

Prognostic Value of Right Ventricular Longitudinal Strain in Patients with COVID-19

Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction

Prognostic Value of Right Ventricular Dysfunction in Heart Failure With Reduced Ejection Fraction -Superiority of Longitudinal Strain Over Tricuspid Annular Plane Systolic Excursion

Mechanism of circulatory responses to systemic hypoxia in the anesthetized dog

Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic

Age and gender specific normal values of left ventricular mass, volume and function for gradient echo magnetic resonance imaging: a cross sectional study

Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance

Normalized Left Ventricular Systolic and Diastolic Function by Steady State Free Precession Cardiovascular Magnetic Resonance

 (1a)) and severe (Test (1b)) COVID-19 infections in an individual with otherwise normal cardiac function (baseline), and computed outputs. For the pulmonary resistances and maximum active elastances current values are derived by the baseline ones owing to equations (1) and (2). Pictures of computed outputs in Figure  3A .